Expanded Utilization of Intralesional Therapies for Treatment of Peyronie’s Disease

References

• Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie’s disease: a case-control study. BJU Int. 2006;97(3):570–574. doi:10.1111/j.1464-410X.2006.05969.x
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Oktar T, Kandirali E, Kendirci M, Sanli O, Ozsoy C. Incidentally diagnosed Peyronie’s disease in men presenting with erectile dysfunction. Int J Impot Res. 2004;16(6):540–543. doi:10.1038/sj.ijir.3901247
   PubMed Web of Science ®Google Scholar
• Randhawa K, Shukla CJ. Non-invasive treatment in the management of Peyronie’s disease. Ther Adv Urol. 2019;11:1756287218823671. doi:10.1177/1756287218823671
   Web of Science ®Google Scholar
• Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol. 1975;114(6):898–900. doi:10.1016/s0022-5347(17)67169-6
   PubMed Web of Science ®Google Scholar
• Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522–1524. doi:10.1016/s0022-5347(17)35291-6
   PubMed Web of Science ®Google Scholar
• Xiaflex prescribing information; 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125338s109lbl.pdf. Accessed December 20, 2022.
   Google Scholar
• Cwikla DJ, Yafi FA. Intralesional collagenase Clostridium histolyticum in the management of Peyronie’s disease: current best practice. Ther Adv Urol. 2018;10(4):139–153. doi:10.1177/1756287218755020
   PubMed Web of Science ®Google Scholar
• Gelbard M, Goldstein I, Hellstrom WJG, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled Phase 3 studies. J Urol. 2013;190(1):199–207. doi:10.1016/j.juro.2013.01.087
   PubMed Web of Science ®Google Scholar
• Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745–753. doi:10.1016/j.juro.2015.05.098
   PubMed Web of Science ®Google Scholar
• Chung E, Ralph D, Kagioglu A, et al. Evidence-based management guidelines on Peyronie’s disease. J Sex Med. 2016;13(6):905–923. doi:10.1016/j.jsxm.2016.04.062
   PubMed Web of Science ®Google Scholar
• EAU. EAU guidelines on sexual and reproductive health. Presented at: EAU Annual Congress; 2023; Milan.
   Google Scholar
• Martínez-Salamanca JI, Egui A, Moncada I, et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11(2):506–515. doi:10.1111/jsm.12400
   PubMed Web of Science ®Google Scholar
• Chung E, De Young L, Solomon M, Brock GB. Peyronie’s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie’s disease in a cell-culture strain system. J Sex Med. 2013;10(5):1259–1267. doi:10.1111/jsm.12082
   PubMed Web of Science ®Google Scholar
• Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW. Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease. Urology. 2017;104:102–109. doi:10.1016/j.urology.2017.01.054
   PubMed Web of Science ®Google Scholar
• Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie’s disease. J Sex Med. 2019;16(6):891–900. doi:10.1016/j.jsxm.2019.03.007
   PubMed Web of Science ®Google Scholar
• Ziegelmann M, Savage J, Toussi A, et al. Outcomes of a novel penile traction device in men with Peyronie’s disease: a randomized, single-blind, controlled trial. J Urol. 2019;202(3):599–610. doi:10.1097/JU.0000000000000245
   PubMed Web of Science ®Google Scholar
• Yafi FA, Hatzichristodoulou G, DeLay KJ, Hellstrom WJG. Review of management options for patients with atypical Peyronie’s disease. Sex Med Rev. 2017;5(2):211–221. doi:10.1016/j.sxmr.2016.07.004
   PubMed Web of Science ®Google Scholar
• Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s disease. J Sex Med. 2012;9(1):288–295. doi:10.1111/j.1743-6109.2011.02519.x
   PubMed Web of Science ®Google Scholar
• Yafi FA, Pinsky MR, Stewart C, et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie’s disease. J Urol. 2015;194(3):754–758. doi:10.1016/j.juro.2015.03.092
   PubMed Web of Science ®Google Scholar
• Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie’s disease with collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med. 2017;14(11):1430–1437. doi:10.1016/j.jsxm.2017.08.015
   PubMed Web of Science ®Google Scholar
• Yang KK, Bennett N. Peyronie’s disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology. 2016;94:143–147. doi:10.1016/j.urology.2016.04.049
   PubMedGoogle Scholar
• Nguyen HMT, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJG. Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie’s disease. J Sex Med. 2017;14(10):1220–1225. doi:10.1016/j.jsxm.2017.08.008
   PubMed Web of Science ®Google Scholar
• Hu MYY, Sigalos JT, Walker DT, et al. Intralesional collagenase Clostridium histolyticum for acute phase Peyronie’s disease: a single-center, retrospective cohort study. Transl Androl Urol. 2022;11(8):1074–1082. doi:10.21037/tau-22-188
   PubMed Web of Science ®Google Scholar
• El-Khatib FM, Osman MM, Kopelevich A, Towe M, Yafi FA. Treatment-related outcomes for patients with atypical Peyronie’s disease using xiaflex injections. Urology. 2020;143:153–158. doi:10.1016/j.urology.2020.05.076
   PubMed Web of Science ®Google Scholar
• Alom M, Meng Y, Sharma KL, Savage J, Kohler T, Trost L. Safety and efficacy of collagenase clostridium histolyticum in Peyronie’s disease men with ventral curvatures. Urology. 2019;129:119–125. doi:10.1016/j.urology.2019.01.055
   PubMedGoogle Scholar
• Sangkum P, Yafi FA, Kim H, et al. Collagenase Clostridium histolyticum (Xiaflex) for the treatment of urethral stricture disease in a rat model of urethral fibrosis. Urology. 2015;86(3):647.e1–6. doi:10.1016/j.urology.2015.06.013
   PubMed Web of Science ®Google Scholar
• Cocci A, Di Maida F, Russo GI, et al. How atypical penile curvature influence clinical outcomes in patients with Peyronie’s disease receiving collagenase clostridium histolyticum therapy? World J Mens Health. 2020;38(1):78–84. doi:10.5534/wjmh.190026
   PubMedGoogle Scholar
• Flores JM, Nascimento B, Punjani N, et al. Predictors of curvature improvement in men with Peyronie’s disease treated with intralesional collagenase clostridium histolyticum. J Sex Med. 2022;19:1680–1686. doi:10.1016/j.jsxm.2022.08.001
   PubMed Web of Science ®Google Scholar
• Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L. Plaque calcification: an important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie’s disease. Urology. 2018;119:109–114. doi:10.1016/j.urology.2018.06.003
   PubMed Web of Science ®Google Scholar
• Margolin EJ, Pagano MJ, Aisen CM, Onyeji IC, Stahl PJ. Beyond curvature: prevalence and characteristics of penile volume-loss deformities in men with Peyronie’s disease. Sex Med. 2018;6(4):309–315. doi:10.1016/j.esxm.2018.07.003
   PubMed Web of Science ®Google Scholar
• Traeger M, Leiber-Caspers C, Chierigo F, Cakir OO, Gratzke C, Schlager D. Penile autophotography underestimates the degree of penile curvature in Peyronie’s disease. Eur Urol Focus. 2023;9(1):64–68. doi:10.1016/j.euf.2022.10.009
   PubMedGoogle Scholar
• Ziegelmann MJ, Heslop D, Houlihan M, et al. The influence of indentation deformity on outcomes with intralesional collagenase clostridium histolyticum monotherapy for Peyronie’s disease. Urology. 2020;139:122–128. doi:10.1016/j.urology.2020.01.035
   PubMed Web of Science ®Google Scholar
• Levine L, Rybak J, Corder C, Farrel MR. Peyronie’s disease plaque calcification--prevalence, time to identification, and development of a new grading classification. J Sex Med. 2013;10(12):3121–3128. doi:10.1111/jsm.12334
   PubMed Web of Science ®Google Scholar
• Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, Phase III studies. BJU Int. 2015;116(4):650–656. doi:10.1111/bju.13096
   PubMed Web of Science ®Google Scholar
• Masterson TA, Atuluru P, Zucker I, et al. Collagenase Clostridium histolyticum treatment improves degree of curvature in Peyronie’s disease with calcified plaques. Eur Urol Focus. 2022;S2405-4569(22)00228–0. doi:10.1016/j.euf.2022.09.019
   Google Scholar
• Teloken P, Katz D. Medical management of Peyronie’s disease: review of the clinical evidence. Med Sci. 2019;7(9):96. doi:10.3390/medsci7090096
   Google Scholar
• Ehrlich HP, Ross R, Bornstein P. Effects of antimicrotubular agents on the secretion of collagen. A biochemical and morphological study. J Cell Biol. 1974;62(2):390–405. doi:10.1083/jcb.62.2.390
   PubMed Web of Science ®Google Scholar
• Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie’s disease: a review. Int J Impot Res. 2002;14(5):324–328. doi:10.1038/sj.ijir.3900917
   PubMed Web of Science ®Google Scholar
• Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res. 1990;49(5):463–466. doi:10.1016/0022-4804(90)90197-a
   PubMed Web of Science ®Google Scholar
• Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A. 1996;93(11):5478–5482. doi:10.1073/pnas.93.11.5478
   PubMed Web of Science ®Google Scholar
• Chong W, Tan RBW. Injectable therapy for Peyronie’s disease. Transl Androl Urol. 2016;5(3):310–317. doi:10.21037/tau.2016.03.15
   PubMed Web of Science ®Google Scholar
• Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol. 1997;158(4):1395–1399. doi:10.1016/S0022-5347(01)64224-1
   PubMed Web of Science ®Google Scholar
• Gallo L, Sarnacchiaro P. Ten-year experience with multimodal treatment for acute phase Peyronie’s disease: a real life clinical report. Actas Urol Esp. 2019;43(4):182–189. doi:10.1016/j.acuro.2018.08.005
   PubMed Web of Science ®Google Scholar
• Wolff B, Peyronnet B, Cattarino S, et al. Intralesional injections for early peyronie disease: standardized assessment and analysis of predictive factors for treatment response. Urology. 2015;86(1):57–61. doi:10.1016/j.urology.2015.03.010
   PubMed Web of Science ®Google Scholar
• Stewart CA, Yafi FA, Knoedler M, et al. Intralesional injection of interferon-α2b improves penile curvature in men with Peyronie’s disease independent of plaque location. J Urol. 2015;194(6):1704–1707. doi:10.1016/j.juro.2015.06.096
   PubMed Web of Science ®Google Scholar
• Yu CJ, Ko CJ, Hsieh CH, et al. Proteomic analysis of osteoarthritic chondrocyte reveals the hyaluronic acid-regulated proteins involved in chondroprotective effect under oxidative stress. J Proteomics. 2014;99:40–53. doi:10.1016/j.jprot.2014.01.016
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Zucchi A, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie’s disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017;5(4):771–775. doi:10.1111/andr.12368
   PubMed Web of Science ®Google Scholar
• Cocci A, Di Maida F, Cito G, et al. Comparison of intralesional hyaluronic acid vs. verapamil for the treatment of acute phase Peyronie’s disease: a prospective, open-label non-randomized clinical study. World J Mens Health. 2021;39(2):352–357. doi:10.5534/wjmh.190108
   PubMedGoogle Scholar
• Gennaro R, Barletta D, Paulis G. Intralesional hyaluronic acid: an innovative treatment for Peyronie’s disease. Int Urol Nephrol. 2015;47(10):1595–1602. doi:10.1007/s11255-015-1074-1
   PubMed Web of Science ®Google Scholar
• Zucchi A, Costantini E, Cai T, et al. Intralesional injection of hyaluronic acid in patients affected with Peyronie’s disease: preliminary results from a prospective, multicenter, pilot study. Sex Med. 2016;4(2):e83–88. doi:10.1016/j.esxm.2016.01.002
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100–119. doi:10.1016/j.eururo.2008.09.009
   PubMed Web of Science ®Google Scholar
• Reddy AG, Dick BP, Natale C, Akula KP, Yousif A, Hellstrom WJG. Application of botulinum neurotoxin in male sexual dysfunction: where are we now? Sex Med Rev. 2021;9(2):320–330. doi:10.1016/j.sxmr.2020.05.004
   PubMed Web of Science ®Google Scholar